Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Alfieri

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|August 8, 2022
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Biochemical Pharmacology|July 3, 2023
Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesotheliomaValentina Coccè, Mara Bonelli, Silvia La Monica, et al.
Biochemical Pharmacology|November 29, 2024
Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678]Valentina Coccè, Mara Bonelli, Silvia La Monica, et al.
Frontiers in Oncology|December 23, 2024
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
European Journal of Medicinal Chemistry|November 26, 2018
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFRRiccardo Castelli, Nicole Bozza, Andrea Cavazzoni, et al.
Biochemical Pharmacology|June 29, 2024
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatmentsClaudia Fumarola, Silvia La Monica, Mara Bonelli, et al.
Cancers|April 26, 2025
Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> 2020, <i>12</i>, 666Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Cancers|March 18, 2020
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung CancerAndrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Biochemical Pharmacology|March 24, 2024
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell linesKamal Eltayeb, Roberta Alfieri, Claudia Fumarola, et al.
Plos Genetics|January 6, 2017
SBDS-Deficient Cells Have an Altered Homeostatic Equilibrium due to Translational Inefficiency Which Explains their Reduced Fitness and Provides a Logical Framework for InterventionPiera Calamita, Annarita Miluzio, Arianna Russo, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|August 8, 2022
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
Biochemical Pharmacology|July 3, 2023
Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesotheliomaValentina Coccè, Mara Bonelli, Silvia La Monica, et al.
Biochemical Pharmacology|November 29, 2024
Corrigendum to "Mesenchymal stromal cells loaded with Paclitaxel (PacliMES) a potential new therapeutic approach on mesothelioma" [Biochem. Pharmacol. 214 (2023) 115678]Valentina Coccè, Mara Bonelli, Silvia La Monica, et al.
Frontiers in Oncology|December 23, 2024
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cellsGraziana Digiacomo, Claudia Fumarola, Silvia La Monica, et al.
European Journal of Medicinal Chemistry|November 26, 2018
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFRRiccardo Castelli, Nicole Bozza, Andrea Cavazzoni, et al.
Biochemical Pharmacology|June 29, 2024
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatmentsClaudia Fumarola, Silvia La Monica, Mara Bonelli, et al.
Cancers|April 26, 2025
Correction: Cavazzoni et al. Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. <i>Cancers</i> 2020, <i>12</i>, 666Andrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Cancers|March 18, 2020
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung CancerAndrea Cavazzoni, Graziana Digiacomo, Roberta Alfieri, et al.
Biochemical Pharmacology|March 24, 2024
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell linesKamal Eltayeb, Roberta Alfieri, Claudia Fumarola, et al.
Plos Genetics|January 6, 2017
SBDS-Deficient Cells Have an Altered Homeostatic Equilibrium due to Translational Inefficiency Which Explains their Reduced Fitness and Provides a Logical Framework for InterventionPiera Calamita, Annarita Miluzio, Arianna Russo, et al.
Pageof 10